Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605948 | 0.86 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL17134055 | 0.83 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL10706522 | 0.83 | NR1H2 (0.32) | ALDH1A1TSHR | |
| SCHEMBL3371 | 0.81 | TSHR (0.48) | ALDH1A1TSHRMAPK1 | |
| Water SCHEMBL27821326 | 0.81 | TSHR (0.48) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL5838774 | 0.81 | ESR1 (0.38) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL24702 | 0.81 | TSHR (0.35) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL3891340 | 0.79 | TSHR (0.46) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL20526431 | 0.79 | TSHR (0.46) | ALDH1A1TSHRMAPK1 | |
| Benzene SCHEMBL8005754 | 0.79 | TSHR (0.52) | ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | claimed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | claimed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-3983073-A1 | SUBSTITUTED PYRAZOLO[4,3-B]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | claimed |
| CN-113993583-A | Substituted pyrazolo [4,3-b ] pyridines and their use as modulators of the GLUN2B receptor | 詹森药业有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-02 | — | — | US | claimed |
| CN-109071488-B | Substituted 1,2, 3-triazoles as NR 2B-selective NMDA modulators | 詹森药业有限公司 | 2021-08-13 | — | — | CN | claimed |
| US-20200392130-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | claimed |
| WO-2020249791-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | claimed |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-08 | — | — | US | claimed |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-09 | — | — | US | claimed |
| CN-109071488-A | Substituted 1,2,3- triazole is as NR2B- selective NMDA regulator | 詹森药业有限公司 | 2018-12-21 | — | — | CN | claimed |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | claimed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| WO-2023178130-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-2010504-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007118900-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007119055-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392130-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN3B, GRIN3A | ALDH1A1 2061/4885TSHR 722/4885MAPK1 1228/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ALDH1A1 472/4885TSHR 1023/4885MAPK1 4544/4885 |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | ALDH1A1 3429/4885TSHR 1034/4885MAPK1 1716/4885 |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | GRIN2B, GRIN3B, GRIN3A | ALDH1A1 2061/4885TSHR 722/4885MAPK1 1228/4885 |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | ALDH1A1 3429/4885TSHR 1034/4885MAPK1 1716/4885 |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | ALDH1A1 3429/4885TSHR 1034/4885MAPK1 1716/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ALDH1A1 450/4885TSHR 1036/4885MAPK1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.